Cascade Pharmaceuticals, Inc
Clinical trials sponsored by Cascade Pharmaceuticals, Inc, explained in plain language.
-
New hope for rare liver disease: experimental drug CS0159 enters phase 2 trial
Disease control OngoingThis study tests a new drug called CS0159 in 50 adults with primary sclerosing cholangitis (PSC), a rare liver disease. The goal is to see if the drug is safe and can improve liver health by lowering certain liver enzyme levels. Participants will receive either CS0159 or a placeb…
Phase: PHASE2 • Sponsor: Cascade Pharmaceuticals, Inc • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New hope for PBC patients: experimental drug CS0159 enters Mid-Stage trial
Disease control OngoingThis study tests a new drug called CS0159 for people with primary biliary cholangitis (PBC), a chronic liver disease. About 75 adults who have not responded well to standard treatment will receive either CS0159 or a placebo for 12 weeks, followed by an open-label period. The goal…
Phase: PHASE2 • Sponsor: Cascade Pharmaceuticals, Inc • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New MASH drug enters early safety testing
Disease control OngoingThis early-stage study tests a new drug called CS060304 in healthy volunteers and people with high LDL cholesterol. The main goal is to check safety and how the drug moves through the body. It is a first step toward finding a treatment for MASH, a serious liver disease.
Phase: PHASE1 • Sponsor: Cascade Pharmaceuticals, Inc • Aim: Disease control
Last updated May 05, 2026 11:53 UTC